0001720580-26-000037
SEC filingNet loss narrowed 28% YoY to $20.2M, driven by disciplined cost reductions, as Adicet advances prula-cel toward pivotal trials.
Adicet's operating loss for Q1 2026 was $21.6 million, a 27.8% improvement from $29.9 million in Q1 2025. Net loss narrowed 28.2% to $20.2 million from $28.2 million. The improvement was driven by disciplined cost management, including reductions in research and development and general and administrative expenses, as the company focuses resources on advancing its lead pipeline candidate, prula-cel.
Adicet's narrative centers on prula-cel, its allogeneic gamma delta CAR-T therapy for autoimmune diseases. The company plans to meet with the FDA in Q2 2026 to align on pivotal trial design for lupus nephritis and systemic lupus erythematosus, with start-up activities expected in H2 2026. A clinical update from at least 20 patients with six months of follow-up is anticipated in mid-2026. Separately, ADI-212, a next-generation candidate for metastatic castration-resistant prostate cancer, is on track for a regulatory filing in Q3 2026. The company's ability to execute on these milestones without additional near-term financing will be critical, as the current cash runway provides limited buffer for delays or expanded development scope.